[sheet: Agreement Matrix]

[sheet: Agreement Matrix]
Agreement ID | Agreement Name | Agreement Type | Effective Date | Parties — Licensor / Service Provider | Parties — Licensee / Service Recipient | Territory / Scope | Key Terms Summary | Pricing Mechanism / Rate | Annual Value — 2017 (USD) | Annual Value — 2018 (USD) | Annual Value — 2019 (USD) | Annual Value — 2020 (USD) | Applicable Treasury Regulation | IRS Exam Relevance | Amendment History | Status | Document Custodian | IDR(s) Referencing Agreement | Notes
ICA-001 | Qualified Cost-Sharing Arrangement (CSA) | Cost-Sharing Arrangement | July 1, 2012 | Penterra Pharmaceuticals Corp. (PPC) — 2200 Independence Boulevard, Princeton Junction, NJ 08550 (EIN 22-3741856) | Penterra Biopharma International DAC (PBI) — 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland (Irish Tax Ref: 3218764T) | PBI acquires rights to develop and exploit PPC pharmaceutical IP portfolio outside the Americas (North America, Central America, South America, Caribbean) | PBI co-funds qualified R&D costs proportional to reasonably anticipated benefits (RAB). Platform Contribution Transaction (PCT) lump-sum payment of $312,000,000 paid by PBI to PPC on July 1, 2012 for buy-in to pre-existing IP (primarily clinical-stage and approved oncology compounds). Cost-sharing ratios based on projected revenue splits. | Cost-sharing ratio: PBI share — 2017: 38.2% ($186.15M of $487.3M total R&D); 2018: 39.6% ($207.42M of $523.8M); 2019: 41.1% ($230.65M of $561.2M); 2020: 42.7% ($255.52M of $598.4M). PCT: $312M lump sum (C&H/Whitmore DCF range: $278M–$361M at 9.8% WACC; IRS valued at $852M at 7.2% WACC). | $186,150,000 | $207,420,000 | $230,650,000 | $255,520,000 | Treas. Reg. § 1.482-7 (Qualified Cost-Sharing Arrangements); IRC § 482 | Primary exam target. IRS proposed increasing PBI cost-share % by 8–12 pp (to 48.2%/50.6%/52.3%/53.7%). Total proposed CSA adjustment: $235,010,000. IRS also challenged PCT valuation ($540M delta). IRS Economist Dr. Alan Washburne provided economic analysis. Settled at Appeals for portion of total $47.6M adjustment. | Original agreement effective July 1, 2012. No material amendments during 2017–2020. | Active | Marcus Whitfield, VP Global Tax (PPC); original documentation prepared by Susan Lam, Crestfield & Associates LLP | IDR No. 2 (agreement and amendments); IDR No. 5 (PCT valuation and workpapers); IDR No. 6 (R&D cost pool and allocation methodology) | Contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP for all four years. PBI incorporated March 15, 2012; CSA effective July 1, 2012. PBI owned 100% by Penterra Holdings Luxembourg S.à r.l. (PHL), which is 100% owned by PPC. PHL treated as disregarded entity for U.S. federal tax purposes.
ICA-002 | Legacy IP License Agreement | Intangible Property License | July 1, 2012 | Penterra Pharmaceuticals Corp. (PPC) | Penterra Biopharma International DAC (PBI) | Non-Americas territories — license of pre-2012 vintage legacy compounds not covered by the CSA | PBI licenses certain legacy pharmaceutical compounds (pre-2012 vintage, excluded from CSA scope) from PPC for commercialization in non-Americas territory. Royalty rate of 4.5% of net sales. Key legacy products include declining-lifecycle compounds with decreasing non-Americas revenues. | Royalty rate: 4.5% of net sales (non-Americas). PPC position supported by CUT analysis: 14 comparable pharmaceutical license agreements identified by Whitmore Valuation Group; IQR 3.1%–6.8%, median 4.4%. IRS proposed increasing rate to 11.0%. | $36,657,000 | $34,303,500 | $31,131,000 | $28,084,500 | Treas. Reg. § 1.482-4 (Methods to determine arm's-length consideration for intangible property); IRC § 482 | Secondary exam target. IRS proposed royalty rate increase from 4.5% to 11.0% (6.5 pp delta). Total proposed royalty adjustment: $188,040,000 ($52.95M + $49.55M + $44.97M + $40.57M). IRS cited different CUT data. Settled at Appeals as part of total $47.6M adjustment. | Original agreement effective July 1, 2012. No material amendments during 2017–2020. | Active | Marcus Whitfield, VP Global Tax (PPC) | IDR No. 3 (license agreement); IDR No. 25 (comparable license agreements / CUT support) | Legacy compound non-Americas net sales declining: 2017: $814.6M; 2018: $762.3M; 2019: $691.8M; 2020: $624.1M. Correlative offset of ($42,650,000) allowed by exam between CSA and royalty adjustments to avoid double-counting.
ICA-003 | Contract Manufacturing Agreement | Manufacturing Services | July 1, 2012 | Penterra Manufacturing Ireland Ltd. (PMI) — Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland (Irish CRO No. 512347) | Penterra Biopharma International DAC (PBI) | Non-Americas markets — contract manufacture of PPC oncology and immunology biologics for PBI's non-Americas distribution | PMI operates as contract manufacturer of PPC's oncology and immunology biologics for non-Americas markets under a cost-plus arrangement with PBI. PMI employs 620 staff. PMI is a controlled entity within the PPC group. | Cost + 8% markup on total manufacturing costs | See PMI financial statements | See PMI financial statements | See PMI financial statements | See PMI financial statements | Treas. Reg. § 1.482-3 (cost-plus method); IRC § 482 | Reviewed by IRS exam team but not a primary adjustment target. Supports PBI's characterization as principal bearing market risk and owning IP for non-Americas territory. Cost-plus 8% tested under arm's-length standard. | Original agreement effective July 1, 2012. Minor operational amendments (production capacity expansion, product line additions). | Active | Marcus Whitfield, VP Global Tax (PPC); Aidan Naughton, Managing Director (PBI) | IDR No. 10 (intercompany manufacturing agreement) | PMI is an Irish private limited company. PBI directs manufacturing priorities and product specifications. PMI's markup tested under comparable profits method.
ICA-004 | Intercompany Services Agreement — R&D Support Services | Services Agreement | January 1, 2014 | Penterra Pharmaceuticals Corp. (PPC) | Penterra Biopharma International DAC (PBI) | Global — PPC provides centralized R&D support services (lab facilities, clinical trial management, data analytics) to PBI in connection with CSA-funded development activities | PPC provides certain centralized R&D support services to PBI that are ancillary to the CSA. Services include access to U.S.-based research facilities, clinical trial coordination, and scientific data management. Charges allocated on a cost basis with appropriate markup. | Cost + 5% markup; allocated based on headcount and usage metrics | See intercompany invoices | See intercompany invoices | See intercompany invoices | See intercompany invoices | Treas. Reg. § 1.482-9 (services); IRC § 482 | Reviewed by IRS in context of DEMPE function analysis. IRS asserted key DEMPE functions remained in U.S.; PPC/C&H rebutted by demonstrating PBI's substantive decision-making, risk management, and control over non-Americas commercialization (185 employees, 42 board meetings in Dublin, €47.2M regulatory spend, independent pricing across 68 country markets). | Original effective January 1, 2014; annual renewals. | Active | Marcus Whitfield, VP Global Tax (PPC) | IDR No. 14 (intercompany service fees — extension requested Sept. 20, 2022) | Service charges distinct from CSA cost-sharing payments. IRS economic substance challenge addressed PBI's role under DEMPE framework.
ICA-005 | Intercompany Services Agreement — Commercial and Marketing Support | Services Agreement | January 1, 2014 | Penterra Biopharma International DAC (PBI) | Penterra Pharmaceuticals Corp. (PPC) | Non-Americas — PBI provides market intelligence, regulatory strategy, and commercial insights from non-Americas markets back to PPC for global strategy purposes | PBI provides PPC with market intelligence, competitive analysis, and regulatory strategy inputs from non-Americas territories. PBI bears costs of its own commercial team and charges PPC for specific cross-border support services. | Cost + 5% markup; allocated based on project hours and deliverables | See intercompany invoices | See intercompany invoices | See intercompany invoices | See intercompany invoices | Treas. Reg. § 1.482-9 (services); IRC § 482 | Supports PBI substance defense — demonstrates PBI's active commercial role and independent decision-making capacity. Evidence of PBI's independent pricing decisions across 68 country markets. | Original effective January 1, 2014; annual renewals. | Active | Aidan Naughton, Managing Director (PBI) | IDR No. 35 (intercompany pricing decisions and market strategy documents) | PBI office: ~18,000 sq ft at Sandyford Business Park, Dublin. PBI headcount grew from 52 (2012) to 185 (2020).
ICA-006 | Intercompany Services Agreement — IT and Administrative Services | Services Agreement | January 1, 2013 | Penterra Pharmaceuticals Corp. (PPC) | Penterra Biopharma International DAC (PBI) and Penterra Manufacturing Ireland Ltd. (PMI) | Global — PPC provides centralized IT infrastructure, ERP systems, and administrative support to Irish entities | PPC provides centralized IT, enterprise resource planning (ERP), cybersecurity, and administrative support services to PBI and PMI. Costs allocated based on headcount proportions and system usage. | Cost + 3% markup; allocated by headcount ratio | See intercompany invoices | See intercompany invoices | See intercompany invoices | See intercompany invoices | Treas. Reg. § 1.482-9 (services); IRC § 482 | Background agreement reviewed by IRS but not a significant adjustment target. | Original effective January 1, 2013; renewed annually with periodic rate adjustments. | Active | Marcus Whitfield, VP Global Tax (PPC) | IDR No. 14 (intercompany service fees) | Standard low-value-adding intra-group services.
ICA-007 | Intercompany Services Agreement — Regulatory and Quality Assurance Support | Services Agreement | January 1, 2015 | Penterra Biopharma International DAC (PBI) | Penterra Pharmaceuticals Corp. (PPC) and Penterra Manufacturing Ireland Ltd. (PMI) | Non-Americas — PBI provides regulatory affairs coordination and quality assurance oversight for non-Americas product registrations and manufacturing compliance | PBI manages regulatory submissions and quality assurance for non-Americas markets. PBI incurred cumulative €47.2M in regulatory expenditures (2017–2020) across 68 country markets. PBI's regulatory team independently manages market authorizations. | Cost + 5% markup for services provided to PMI; costs borne directly by PBI for its own regulatory activities | See intercompany invoices | See intercompany invoices | See intercompany invoices | See intercompany invoices | Treas. Reg. § 1.482-9 (services); IRC § 482 | Key evidence supporting PBI economic substance and DEMPE functions (Maintenance, Enhancement, Exploitation). PBI's €47.2M cumulative regulatory spend (2017–2020) and management of 68 country-market registrations demonstrated substantive local functions. | Original effective January 1, 2015; renewed annually. | Active | Aidan Naughton, Managing Director (PBI) | IDR No. 15 (regulatory expenditures and submissions) | PBI independently managed regulatory submissions across EMEA and APAC. Board oversight documented in 42 board meetings (2017–2020), all held in Dublin.
ICA-008 | Intercompany Trademark License Agreement | Intangible Property License | July 1, 2012 | Penterra Pharmaceuticals Corp. (PPC) | Penterra Biopharma International DAC (PBI) | Non-Americas — license of PPC trademarks and trade names for use in non-Americas marketing and distribution of Veritaxol, Imvara, and Cerulon | PBI licensed PPC trademarks and trade names for use in non-Americas commercialization. Key products: Veritaxol (oncology — 2020 non-Americas net sales $1.34B), Imvara (immunology — $0.79B), Cerulon (rare disease — $0.28B). Royalty bundled with legacy IP license or charged at nominal rate. | Nominal royalty / bundled with ICA-002 legacy IP license; no separate material charge | Bundled | Bundled | Bundled | Bundled | Treas. Reg. § 1.482-4; IRC § 482 | Reviewed by IRS in context of overall IP transfer pricing analysis. Not a separate adjustment target; subsumed within royalty and CSA analysis. | Effective July 1, 2012; coterminous with legacy IP license and CSA. | Active | Marcus Whitfield, VP Global Tax (PPC) | IDR No. 3 (part of license agreement package) | Trademark value considered ancillary to pharmaceutical IP in CUT and CPM analyses.
[sheet: Corporate Structure]
Entity | Full Legal Name | Entity Type | Jurisdiction | Registered Address | Tax ID / Reference | Parent Entity | Ownership % | U.S. Tax Classification | Role in Group | Employees (2020) | Key Contact
PPC | Penterra Pharmaceuticals Corp. | Corporation | Delaware; HQ in NJ | 2200 Independence Boulevard, Princeton Junction, NJ 08550 | EIN 22-3741856 | N/A — ultimate parent (publicly traded, Nasdaq: PPCA) | N/A | U.S. C corporation | Ultimate parent; U.S. operating company; IP developer and licensor; CSA participant (Americas territory) | ~14,500 (global) | Marcus Whitfield, VP Global Tax; Catherine Falk, CEO; Rajesh Iyer, CFO; Deborah Staines, General Counsel
PHL | Penterra Holdings Luxembourg S.à r.l. | Société à responsabilité limitée | Luxembourg | 14, rue Aldringen, L-1118 Luxembourg | RCS Number B 168452 | Penterra Pharmaceuticals Corp. | 100% | Disregarded entity for U.S. federal tax purposes | Intermediate holding company; 100% owner of PBI | N/A (holding entity) | N/A
PBI | Penterra Biopharma International DAC | Designated Activity Company | Ireland | 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland | Irish Tax Ref: 3218764T | Penterra Holdings Luxembourg S.à r.l. | 100% | Controlled foreign corporation (CFC) — check-the-box election not made; treated as separate entity | IP-holding company and principal for non-Americas commercialization; CSA participant; licensee of legacy IP; manages contract manufacturing and distribution across EMEA and APAC | 185 | Aidan Naughton, Managing Director
PMI | Penterra Manufacturing Ireland Ltd. | Irish private limited company | Ireland | Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland | Irish CRO No. 512347 | Penterra Biopharma International DAC (or PPC — within group) | 100% | Controlled foreign corporation (CFC) | Contract manufacturer of oncology and immunology biologics for non-Americas markets under cost-plus arrangement with PBI | 620 | N/A
[sheet: IRS Adjustment Summary]
Agreement Ref | Agreement Name | IRS Issue | Tax Year | PPC Position | IRS Position | Proposed Adjustment Amount (USD) | Settlement Allocation (USD) | Applicable Regulation | Defense Method | Notes
ICA-001 | Cost-Sharing Arrangement | CSA Cost-Sharing Ratio | 2017 | PBI share: 38.2% of $487.3M = $186,150,000 | PBI share: 48.2% of $487.3M (+10.0 pp increase) | $48,730,000 | Included in $11,200,000 (2017 total) | Treas. Reg. § 1.482-7 | CPM/TNMM analysis (22 comparables); reasonably anticipated benefits model; Whitmore Valuation Group report | IRS Economist Dr. Alan Washburne analysis rebutted by Dr. Helena Vasquez and Dr. Rohan Chakrabarti (Whitmore)
ICA-001 | Cost-Sharing Arrangement | CSA Cost-Sharing Ratio | 2018 | PBI share: 39.6% of $523.8M = $207,420,000 | PBI share: 50.6% of $523.8M (+11.0 pp increase) | $57,610,000 | Included in $12,400,000 (2018 total) | Treas. Reg. § 1.482-7 | CPM/TNMM analysis; RAB projections
ICA-001 | Cost-Sharing Arrangement | CSA Cost-Sharing Ratio | 2019 | PBI share: 41.1% of $561.2M = $230,650,000 | PBI share: 52.3% of $561.2M (+11.2 pp increase) | $62,850,000 | Included in $12,800,000 (2019 total) | Treas. Reg. § 1.482-7 | CPM/TNMM analysis; RAB projections
ICA-001 | Cost-Sharing Arrangement | CSA Cost-Sharing Ratio | 2020 | PBI share: 42.7% of $598.4M = $255,520,000 | PBI share: 53.7% of $598.4M (+11.0 pp increase) | $65,820,000 | Included in $11,200,000 (2020 total) | Treas. Reg. § 1.482-7 | CPM/TNMM analysis; RAB projections
ICA-001 | Cost-Sharing Arrangement | CSA Subtotal | 2017–2020 | $235,010,000 | Sum of CSA proposed adjustments: $48,730,000 + $57,610,000 + $62,850,000 + $65,820,000
ICA-002 | Legacy IP License Agreement | Royalty Rate | 2017 | 4.5% of $814.6M = $36,657,000 (CUT median 4.4%; IQR 3.1%–6.8%) | 11.0% of $814.6M; delta = 6.5% × $814.6M | $52,950,000 | Included in $11,200,000 (2017 total) | Treas. Reg. § 1.482-4 | CUT analysis — 14 comparable uncontrolled pharmaceutical license agreements; Whitmore Valuation Group report
ICA-002 | Legacy IP License Agreement | Royalty Rate | 2018 | 4.5% of $762.3M = $34,303,500 | 11.0% of $762.3M; delta = 6.5% × $762.3M | $49,550,000 | Included in $12,400,000 (2018 total) | Treas. Reg. § 1.482-4 | CUT analysis
ICA-002 | Legacy IP License Agreement | Royalty Rate | 2019 | 4.5% of $691.8M = $31,131,000 | 11.0% of $691.8M; delta = 6.5% × $691.8M | $44,970,000 | Included in $12,800,000 (2019 total) | Treas. Reg. § 1.482-4 | CUT analysis
ICA-002 | Legacy IP License Agreement | Royalty Rate | 2020 | 4.5% of $624.1M = $28,084,500 | 11.0% of $624.1M; delta = 6.5% × $624.1M | $40,570,000 | Included in $11,200,000 (2020 total) | Treas. Reg. § 1.482-4 | CUT analysis
ICA-002 | Legacy IP License Agreement | Royalty Subtotal | 2017–2020 | $188,040,000 | Sum of royalty proposed adjustments: $52,950,000 + $49,550,000 + $44,970,000 + $40,570,000
N/A | Correlative Offset (CSA/Royalty Overlap) | Overlap / Double-Count Correction | 2017–2020 | Correlative adjustment required to avoid double-counting between CSA and royalty adjustments | Exam allowed offset | ($42,650,000) | N/A | Treas. Reg. § 1.482-1(g) | Research memorandum on correlative adjustments | Offset reduces net proposed adjustment from $423,050,000 to $380,400,000
All | Economic Substance Challenge | PBI lacks sufficient economic substance / DEMPE functions remain in U.S. | 2017–2020 | PBI substantive: 185 employees, 42 board meetings (Dublin), €47.2M regulatory spend, independent pricing across 68 markets, ~18,000 sq ft office, Glenmore Bank Ireland plc banking | Key DEMPE functions remained in U.S. | Supports CSA and royalty adjustments (not a separate $ adjustment) | N/A | IRC § 482; OECD TP Guidelines Ch. VI (DEMPE) | Functional analysis; PBI personnel interviews (12 key employees); board minutes analysis; DEMPE functions matrix | Economic substance challenge rebutted through comprehensive functional analysis prepared by C&H and Whitmore
TOTAL — Gross Proposed Adjustments | 2017–2020 | $423,050,000 | CSA $235,010,000 + Royalty $188,040,000
TOTAL — Net Proposed Adjustments (after correlative offset) | 2017–2020 | $380,400,000 | $423,050,000 – $42,650,000 = $380,400,000
TOTAL — Settlement Amount | 2017–2020 | $47,600,000 | Settlement as % of proposed: $47,600,000 / $380,400,000 = 12.51%. Allocation: 2017: $11,200,000; 2018: $12,400,000; 2019: $12,800,000; 2020: $11,200,000
Tax on Settlement (21%) | 2017–2020 | $9,996,000 | $47,600,000 × 21% = $9,996,000 (rounded to ~$10,000,000)
Proposed Penalty (Fully Abated) | 2017–2020 | $15,977,000 | $0 | IRC § 6662(e)(3)(B) | Reasonable cause / contemporaneous documentation defense | $380,400,000 × 21% × 20% = $15,976,800 (~$15,977,000); fully abated at Appeals
[sheet: Key Terms Reference]
Agreement Ref | Agreement Name | Execution Date | Term / Renewal | Transfer Pricing Method Applied | Benchmarking Analysis | Comparable Set Size | Arm's-Length Range | PPC's Rate/Price | Within Range? | Contemporaneous Documentation | Penalty Protection Status | Supporting Expert Report | IDR Production References | Key Products Covered
ICA-001 | Qualified Cost-Sharing Arrangement | July 1, 2012 | Indefinite; subject to participant termination provisions per Treas. Reg. § 1.482-7(j) | Income Method / DCF (PCT); Comparable Profits Method / TNMM (ongoing cost shares) | CPM/TNMM: PBI operating margins tested against comparable IP-holding and distribution companies | 22 | PBI operating margins within interquartile range in all four years (2017–2020) | CSA shares: 38.2%–42.7%; PCT: $312M | Yes | Prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner; Martin Ogilvy, Engagement Partner) for TY 2017–2020 under IRC § 6662(e) standards | Reasonable cause defense accepted; penalty fully abated at Appeals | Whitmore Valuation Group — CPM/TNMM Analysis Report (Nov. 2022); PCT Valuation DCF Report (Dec. 2022); WACC Analysis by Dr. Helena Vasquez (Dec. 2022) | IDR Nos. 2, 5, 6, 4 | All CSA-covered IP: Veritaxol (oncology — 2020 global: $3.12B, non-Americas: $1.34B), Imvara (immunology — $1.87B/$0.79B), Cerulon (rare disease — $0.62B/$0.28B)
ICA-002 | Legacy IP License Agreement | July 1, 2012 | Coterminous with product lifecycle; renewable annually | Comparable Uncontrolled Transaction (CUT) method | CUT analysis: 14 comparable pharmaceutical license agreements identified | 14 | IQR: 3.1%–6.8%; Median: 4.4% | 4.5% of non-Americas net sales | Yes | Prepared by Crestfield & Associates LLP for TY 2017–2020 | Reasonable cause defense accepted; penalty fully abated | Whitmore Valuation Group — CUT Analysis Royalty Report (Nov. 2022); rebuttal of IRS Economist Dr. Alan Washburne (Jan. 2024) by Dr. Helena Vasquez and Dr. Rohan Chakrabarti | IDR Nos. 3, 25 | Pre-2012 legacy compounds (declining lifecycle); not covered by CSA
ICA-003 | Contract Manufacturing Agreement | July 1, 2012 | Coterminous with CSA/license; renewable annually | Cost-Plus Method | PMI markup tested against comparable contract manufacturers | N/A (tested as part of broader group analysis) | Cost + 8% within arm's-length range for limited-risk contract manufacturers | Cost + 8% | Yes | Included in Crestfield transfer pricing documentation | Covered by contemporaneous documentation | N/A (not primary adjustment target) | IDR No. 10 | Oncology and immunology biologics for non-Americas markets
ICA-004 | R&D Support Services Agreement | January 1, 2014 | Annual renewals; originally effective January 1, 2014 | Services Cost Method / Cost-Plus | Markup tested under Treas. Reg. § 1.482-9; comparable service arrangements reviewed | N/A (ancillary services) | Cost + 5% within arm's-length range for routine R&D support services | Cost + 5% | Yes | Included in Crestfield transfer pricing documentation | Covered by contemporaneous documentation | N/A (reviewed but not primary adjustment target) | IDR No. 14 | Centralized R&D support services ancillary to CSA-funded development activities
ICA-005 | Commercial and Marketing Support Services Agreement | January 1, 2014 | Annual renewals; originally effective January 1, 2014 | Services Cost Method / Cost-Plus | Markup tested under Treas. Reg. § 1.482-9; comparable service arrangements reviewed | N/A (ancillary services) | Cost + 5% within arm's-length range for commercial advisory services | Cost + 5% | Yes | Included in Crestfield transfer pricing documentation | Covered by contemporaneous documentation | N/A (supports PBI substance defense) | IDR No. 35 | Market intelligence, competitive analysis, and regulatory strategy inputs from non-Americas territories
ICA-006 | IT and Administrative Services Agreement | January 1, 2013 | Annual renewals with periodic rate adjustments; originally effective January 1, 2013 | Services Cost Method / Cost-Plus | Low-value-adding intra-group services; markup tested under simplified approach | N/A (low-value-adding services) | Cost + 3% within arm's-length range for low-value-adding IT and administrative services | Cost + 3% | Yes | Included in Crestfield transfer pricing documentation | Covered by contemporaneous documentation | N/A (background agreement; not adjustment target) | IDR No. 14 | Centralized IT infrastructure, ERP systems, cybersecurity, and administrative support
ICA-007 | Regulatory and Quality Assurance Support Agreement | January 1, 2015 | Annual renewals; originally effective January 1, 2015 | Services Cost Method / Cost-Plus | Markup tested under Treas. Reg. § 1.482-9; PBI direct regulatory expenditures analyzed for DEMPE substance | N/A (ancillary services; DEMPE substance analysis) | Cost + 5% within arm's-length range for regulatory coordination services | Cost + 5% | Yes | Included in Crestfield transfer pricing documentation | Covered by contemporaneous documentation | Whitmore Valuation Group — DEMPE Functions Matrix (Dec. 2022); supports PBI substance defense | IDR No. 15 | Regulatory submissions and quality assurance across 68 country markets in EMEA and APAC; cumulative €47.2M regulatory spend (2017–2020)
ICA-008 | Trademark License Agreement | July 1, 2012 | Coterminous with legacy IP license and CSA | CUT / bundled analysis | Trademark value assessed as ancillary to pharmaceutical IP; bundled with ICA-002 CUT analysis | N/A (bundled with ICA-002) | Nominal / bundled — trademark value ancillary to pharmaceutical compound IP | Nominal royalty / bundled | Yes | Included in Crestfield transfer pricing documentation | Covered by contemporaneous documentation | N/A (subsumed within royalty and CSA analysis) | IDR No. 3 | PPC trademarks and trade names for Veritaxol, Imvara, and Cerulon in non-Americas markets
[sheet: Examination Timeline]
Date | Event | Relevant Agreement(s) | Key Participants | Notes
March 15, 2012 | Incorporation of Penterra Biopharma International DAC | All | PPC, PBI | PBI incorporated under Irish law as a Designated Activity Company
July 1, 2012 | CSA effective date; PCT payment of $312,000,000; Legacy IP license and manufacturing agreement effective; Trademark license effective | ICA-001, ICA-002, ICA-003, ICA-008 | PPC, PBI, PMI | All foundational intercompany agreements executed simultaneously
2017–2020 | Tax years under IRS examination | All | PPC (Forms 1120, EIN 22-3741856) | Contemporaneous TP documentation prepared by Crestfield & Associates LLP for each year
May 16, 2022 | IRS examination opened — Letter 2205-A issued | All | IRS Exam Team LB&I-NE-TP-2022-00641 (Gerald Meskill, Team Manager; Patricia Dunleavy, Lead Revenue Agent) | Examination of PPC transfer pricing for TY 2017–2020
June 2, 2022 | Calderwood & Harkness LLP engagement letter executed | All | Leonard Cross (Responsible Partner); Sylvia Hartwell (Billing Partner); Marcus Whitfield (PPC) | C&H Matter No. 1018-00009; billing rates: Cross $1,475/hr, Hartwell $1,350/hr, Simmons $885/hr, Nazari $695/hr
June 8, 2022 | IRS Form 2848 Power of Attorney filed | All | Cross, Hartwell, Simmons, Nazari authorized to represent PPC | PPC EIN 22-3741856; TY 2017–2020
June 20, 2022 | Kovel letter executed — Whitmore Valuation Group LLC retained | ICA-001, ICA-002 | Dr. Helena Vasquez (Lead Economist); reference 1018-00009-KV | Blended rate $650/hr; total fees billed: $2,146,800
June 2022 – September 2023 | 47 IDRs issued and responded to | All | IRS (Dunleavy); C&H (Simmons, Nazari) | IDRs covered CSA, legacy license, manufacturing agreement, PBI substance, financials, Forms 5471
October 12, 2023 | NOPA issued — $380,400,000 proposed adjustments (all four years) | ICA-001, ICA-002 | IRS (Meskill, Dunleavy, Dr. Washburne, Franklin Rosario, Donna Hirabayashi) | CSA: $235,010,000; Royalty: $188,040,000; Correlative Offset: ($42,650,000); Proposed penalty: ~$15,977,000 under IRC § 6662(e)
November 8, 2023 | 30-Day Letter issued | All | IRS to PPC | Options: file Protest to Appeals or petition Tax Court
December 22, 2023 | Formal Protest filed | ICA-001, ICA-002 | C&H (Cross) on behalf of PPC | Contesting all $380,400,000 in proposed adjustments; comprehensive transfer pricing defense
January 2024 | Case assigned to Appeals Officer Noreen Castañeda | All | IRS Appeals
February 28, 2024 | Appeals conference — IRS Appeals Office, Manhattan | ICA-001, ICA-002 | C&H (Cross, Hartwell, Simmons); PPC (Whitfield, Staines); Whitmore (Dr. Vasquez); IRS (Castañeda) | In-person conference
March 15, 2024 | Settlement offer from Appeals — $47,600,000 total adjustment | ICA-001, ICA-002 | Appeals Officer Castañeda | 12.51% of $380,400,000 proposed; full penalty abatement
March 22, 2024 | PPC acceptance of settlement | All | Whitfield, Cross; approved by Iyer (CFO) and Falk (CEO) | Allocation: 2017 $11,200,000 / 2018 $12,400,000 / 2019 $12,800,000 / 2020 $11,200,000
March 29, 2024 | Form 906 Closing Agreement executed; examination closed | All | PPC (Whitfield), IRS Appeals | Tax due: ~$10,000,000; Interest: ~$2,840,000; Penalty: $0; Total cash cost: ~$12,840,000; Total cost to PPC including professional fees: ~$21,165,420